<DOC>
	<DOC>NCT00160225</DOC>
	<brief_summary>This study is to evaluate the end of treatment effect of Daglutril compared to placebo on top of losartan.</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>treated with optimized dose of losartan (constant dose for at least four weeks before randomization and throughout the whole study period) for at least four weeks urinary albumin excretion ≥ 20 and &lt; 1000 µg/min sitting systolic/diastolic blood pressure (SBP/DBP) &lt; 140/90 mmHg at the end of placebo runin phase known secondary hypertension decompensated congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>blood pressure, diabetic nephropathy, proteinuria</keyword>
</DOC>